原標(biāo)題：樺木花粉變應(yīng)原bet v 1定量參考抗體表位特異性特征的鑒定
　?、?免疫治療變應(yīng)原提取物的一致性需要通過精確的定量試驗(yàn)來記錄；② 單克隆抗體5B4對應(yīng)的肽序列與患者血清IgE的結(jié)合位點(diǎn)重疊；③ 單克隆抗體6H4識別與5B4結(jié)合位點(diǎn)相反的構(gòu)象表位；④ 兩種單克隆抗體與樺木花粉提取物中90%以上的Bet v 1有相互作用；⑤ 單克隆抗體5B4和6H4可以識別Bet v 1絕大多數(shù)異構(gòu)體上的不同表位。


　　延伸閱讀


Allergy
Characterization of epitope specificities of reference antibodies used for the quantification of the birch pollen allergen Bet v 1
DOI: 10.1111/all.13364
Abstract:
Background: Accurate allergen quantification is needed to document the consistency of allergen extracts used for immunotherapy. Herein, we characterize the epitope specificities of two monoclonal antibodies used in an ELISA for the quantification of the major birch pollen allergen Bet v 1, established as a reference by the BSP090 European project.
Methods: The ability of mAbs 5B4 and 6H4 to recognize Bet v 1 isoforms was addressed by immunochromatography. The capacity of each mAb to compete with patients’ IgE for binding to Bet v 1 was measured by ELISA inhibition. Epitope mapping was performed by pepscan analysis, site-directed mutagenesis and hydrogen/deuterium exchange-mass spectrometry.
Results: The 5B4 epitope corresponds to a peptide sequence (I56-K68) overlapping with the binding sites of patients’ serum IgEs. Mutation of residues P59, E60 and K65 abolishes 5B4 binding to Bet v 1 and reduces the level of IgE recognition. In contrast, 6H4 recognizes a conformational epitope lying opposite to the 5B4 binding site, involving residues located in segments I44-K55 and R70-F79.Substitution of E45 reduces the binding capacity of 6H4, confirming that it is critical for the interaction. Both mAbs interact with >90% of Bet v 1 content present in the birch pollen extract,while displaying a weak cross-reactivity with other allergens of the PR-10 family.
Conclusions: MAbs 5B4 and 6H4 recognize structurally distinct epitopes present in the vast majority of Bet v 1 isoforms. These results support the relevance as a reference method of the Bet v 1-specific quantitative ELISA adopted by the European Pharmacopoeia.
First Author:
Sébastien Brier
Correspondence:
Emmanuel Nony, Research Department, Stallergenes Greer
All Authors:
Sébastien Brier, Maxime Le Mignon, Karine Jain, Constance Lebrun, Fran?ois Peurois,Christine Kellenberger, Véronique Bordas-Le Floch, Laurent Mascarell, Emmanuel Nony1 and Philippe Moingeon
　　創(chuàng)建過敏性疾病的科研、科普知識交流平臺，為過敏患者提供專業(yè)診斷、治療、預(yù)防的共享平臺。